Panacea Plant Sciences, a Washington State biotechnology company, has discovered formulations that act synergistically with dimethyltryptamine (DMT). The company announced the findings during the Cannabis Science Conference, on May 19.
The data shows increases of more than 200% at the 5-HT2A receptor when the company's PPS1 and PPS2 drug candidates are combined with DMT.
Furthermore, it indicates the ability of PPS drug candidates to make a sub-therapeutic dose of DMT potent enough to be potentially utilized for medical treatments.
The company has filed patents to protect the formulations, PPS1 and PPS2, as its prepares to enter the drug development pipeline. Panacea Plant Sciences expects to publish the complete study in Q3.
“Panacea Plant Sciences believes that synergy of formulations can provide better treatment options at lower prices,” Panacea Plant Sciences CEO David Heldreth said. “We hope this discovery will lead to the creation of cheaper formulations which utilize less of expensive, culturally and environmentally sensitive active compounds like DMT.”
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
The Benzinga Cannabis Capital Conference is coming to Florida
The Benzinga Cannabis Capital Conference is returning to Florida, in a new venue in Hollywood, on April 16 and 17, 2024. The two-day event at The Diplomat Beach Resort will be a chance for entrepreneurs, both large and small, to network, learn and grow. Renowned for its trendsetting abilities and influence on the future of cannabis, mark your calendars – this conference is the go-to event of the year for the cannabis world.
Get your tickets now on bzcannabis.com – Prices will increase very soon!